Repligen Agrees to Acquire ARTeSyn Biosolutions

0

Repligen agreed to acquire ARTeSYN Biosolutions for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock.

The ARTeSYN deal, combined with the recent acquisitions of Engineered Molding Technologies (EMT) and Non-Metallic Solutions (NMS), strengthens Repligen’s capabilities in single-use systems and associated integrated flow path assemblies, according to the company.

ARTeSYN provides single-use systems for chromatography, filtration, continuous manufacturing, and media/buffer prep workflows. In addition, the company has integrated flow path assemblies utilizing EMT’s silicone extrusion and molding technology, to deliver highly differentiated, low hold-up volume systems that minimize product loss during processing, says Tony J. Hunt, president and CEO of Repligen.

“The ARTeSYN portfolio expands on the market success of our hollow fiber systems and complements our market leading chromatography and TFF filtration product lines,” he adds.

NMS, a privately-held company based in Auburn, MA, specializes in plastic fabrication, assembly, standard thermoplastic tanks, as well as rotational molding (rotomolding) technology. NMS primarily services the biopharmaceutical industry, offering products such as USP Class VI polypropylene process vessels, standard or custom-designed mixing bag retainers, custom-machined manifolds, concentric reducers, and a wide range of optimum performance tubing, fittings, accessories and components.

This site uses Akismet to reduce spam. Learn how your comment data is processed.